Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31

Urologic Oncology: Seminars and Original Investigations

Volumn 23, Issue 6, 2005, Pages 462-463

  Pilepich, M V ^a   Winter, K ^a   Lawton, C A ^a   Krisch, R E ^a   Wolkov, H B ^a   Movsas, B ^a   Hug, E B ^a   Asbell, S O ^a   Grignon, D ^a   Carroll, Peter R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ANDROGEN; GOSERELIN;

ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HISTOLOGY; HUMAN; LONG TERM CARE; METASTASIS; MORTALITY; NOTE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL; SURVIVAL RATE; TREATMENT FAILURE; TUMOR DIFFERENTIATION;

EID: 27844583379     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.08.015     Document Type: Short Survey

References (0)